Related Experiment Video
Updated: Jan 24, 2026

Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue
Published on: June 21, 2018
Lactate dehydrogenase 5: identification of a druggable target to reduce oxaluria
Abstract:
Excessive excretion of oxalate in the urine results in the formation of calcium oxalate crystals and subsequent kidney stone formation. Severe forms of hyperoxaluria, including genetic forms and those that result from ethylene glycol poisoning, can result in end-stage renal disease. Therapeutic interventions are limited and often rely on dietary intervention. In this issue of the JCI, Le Dudal and colleagues demonstrate that the lactate dehydrogenase 5 inhibitor (LDH5) stiripentol reduces urinary oxalate excretion. Importantly, stiripentol treatment of a single individual with primary hyperoxaluria reduced the urinary oxalate excretion. Together, these results support further evaluation of LDH5 as a therapeutic target for hyperoxaluria.
Insights
A new study shows stiripentol, a lactate dehydrogenase 5 inhibitor (LDH5), can reduce urinary oxalate excretion. This finding offers a potential new therapeutic target for hyperoxaluria, a condition leading to kidney stones.
Area of Science:
- Nephrology
- Biochemistry
- Metabolic Disorders
Background:
- Hyperoxaluria involves excessive urinary oxalate, leading to calcium oxalate crystals and kidney stones.
- Severe hyperoxaluria, including genetic forms and ethylene glycol poisoning, can cause end-stage renal disease.
- Current therapeutic options for hyperoxaluria are limited, primarily relying on dietary management.
Purpose of the Study:
- To investigate the effect of lactate dehydrogenase 5 (LDH5) inhibition on urinary oxalate excretion.
- To evaluate stiripentol, an LDH5 inhibitor, as a potential therapeutic agent for hyperoxaluria.
Main Methods:
- The study by Le Dudal and colleagues investigated the impact of stiripentol on urinary oxalate levels.
- A single patient with primary hyperoxaluria received stiripentol treatment.
Main Results:
- Stiripentol treatment was shown to reduce urinary oxalate excretion.
- The treated individual with primary hyperoxaluria exhibited decreased urinary oxalate excretion.
Conclusions:
- Lactate dehydrogenase 5 (LDH5) inhibition is a promising therapeutic strategy for reducing urinary oxalate.
- Stiripentol demonstrates potential as a novel treatment for hyperoxaluria and associated kidney stone formation.
- Further research into LDH5 as a therapeutic target for hyperoxaluria is warranted.
More Related Videos
09:34The Lactate Dehydrogenase Sequestration Assay — A Simple and Reliable Method to Determine Bulk Autophagic Sequestration Activity in Mammalian Cells
Published on: July 27, 2018
08:36Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
Published on: May 26, 2018
Related Concept Videos
5-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Adaptations that Reduce Water Loss
Role of Reduced Coenzymes NADH and FADH₂
Redox Titration: Other Oxidizing and Reducing Agents